- Sales Increase 11.9% (9.4% at Constant Currency) to $124.5 Million -
- Excluding Charges, Net Income Increases 13.3% to $10.2 Million -
- Reported Net Income, Including Financing and Other Charges, is $2.8 Million-
UTICA, N.Y., July 17 /PRNewswire-FirstCall/ -- CONMED Corporation
(Nasdaq: CNMD) today announced financial results for the second quarter and
six months ended June 30, 2003.
Total sales for the quarter increased 11.9% (9.4% at constant currency) to
$124.5 million compared to $111.3 million in last year's second quarter. For
the 2003 second quarter, CONMED posted net income, excluding financing,
acquisition, and other charges, of $10.2 million, up 13.3% from net income of
$9.0 million for last year's second quarter. Diluted earnings per share
excluding the charges grew to $0.35, on a 7% increase in diluted shares
outstanding, compared to diluted earnings per share of $0.33 for the 2002
second quarter. In the 2003 second quarter, the Company recorded after-tax
charges totaling $7.4 million related to the refinancing of the Company's
senior subordinated 9% bonds, the acquisitions of Bionx and Core Dynamics, and
settlement of certain pension obligations (please see below for full
explanation). On a generally accepted accounting principles (GAAP) basis,
including these charges, CONMED reported net income of $2.8 million, or $0.09
per diluted share for the second quarter of 2003.
Commenting on the quarter, Mr. Joseph J. Corasanti, President and Chief
Operating Officer, said, "CONMED had a very strong second quarter, with
revenue growth exceeding our projections across almost all product lines.
Most notable was the performance of our powered instruments, electrosurgery
and endoscopy business segments-all of which either met or exceeded our
expectations thanks to the success of new products and the efforts of our
devoted sales teams. Additionally, from an expense control standpoint, we
were able to refinance all of our 9% senior subordinated bonds and as such
will have substantially lower interest costs going forward."
The Company's Arthroscopy sales were $44.4 million, including $4.1 million
in sales from Bionx Implants, Inc., which was acquired by CONMED on March 10,
2003, compared to $41.2 million in the second quarter of last year. Organic
sales for arthroscopy were slightly softer than the prior year's second
quarter, as a 5% increase in sales of resection shaver blades was offset by
modest declines in sales of video systems and fluid management products.
Second quarter Powered Surgical Instrument sales grew 10% to $29.7 million
compared to $27.0 million last year, reflecting continued growth in demand for
the PowerPro(R) group of products. Electrosurgery revenues increased 11% to
$18.9 million compared to $17.0 million in the prior year's second quarter,
due to strong sales of the Company's new generator. Patient Care sales grew
4% to $17.7 million over the $17.1 million recorded in the second quarter of
2002. Endoscopy sales increased 32% to $11.9 million compared to $9.0 million
in the same quarter a year ago. Organic sales growth in Endoscopy was 12%,
rebounding from flat sales in the first quarter of 2003. The remainder of
sales growth in Endoscopy came from Core Dynamics, acquired by CONMED on
December 31, 2002, which contributed $1.8 million for the second quarter. The
Integrated Systems product line, which CONMED obtained through its
acquisitions of ValMed and Nortrex in the fourth quarter of 2002, contributed
$1.9 million to total revenue for the 2003 second quarter.
Mr. Corasanti continued, "As demonstrated by our strong powered
instruments sales, our PowerPro(R) line of battery powered surgical
instruments continues to build momentum within the medical community, fueled
by a 21% increase in large bone product sales. Additionally, our distribution
agreement with DePuy is moving forward, as PowerPro(R) sales to DePuy grew
sequentially from the first quarter. In Electrosurgery, our 11% growth was
led by our newly released Series 5000 electrosugical generators. We continue
to be very excited by the many opportunities in Endoscopy and Integrated
Systems and believe that these businesses will fuel much growth for CONMED
over the coming years."
Mr. Corasanti added, "We are making solid progress in expanding our
orthopedic sales force to maximize coverage in key markets for arthroscopy and
powered instruments. Since announcing our sales strategy this past April, we
have added 30 sales professionals and remain committed to our stated goal of
adding a total of 50 professionals to our orthopedic sales team over the next
twelve months."
For the six months ended June 30, 2003, CONMED reported revenues of
$242.6 million, up 8% from the $224.5 million in the first half of last year.
Net income, excluding special charges and credits, for the first half of this
year grew to $20.2 million, or $0.69 per diluted share, on a 10.5% increase in
diluted shares outstanding, compared to net income of $18.0 million, or $0.68
per diluted share, for the six months ended June 30, 2002 (please see below
for full explanation of the special charges and credits). On a GAAP basis,
including these charges and credits, CONMED reported net income of
$17.3 million, or $0.59 per diluted share for the six months ended June 30,
2003.
Mr. Corasanti concluded, "Seasonally, the upcoming third quarter tends to
be our softest in terms of sales, due to the combination of fewer elective
surgeries performed and overall slowness in European business during the
summer months. Accordingly, for the 2003 third quarter, we expect to generate
revenues of approximately $117 million to $122 million, and diluted earnings
per share, reflecting the reduced interest rates, in the range of $0.35 to
$0.38, excluding special charges, if any. For the full year of 2003, we
remain comfortable with our forecast for top-line growth of 10% over 2002
levels and diluted earnings per share, reflecting the reduced interest costs,
in the range of $1.47 to $1.51 excluding the special charges and credits.
(Please see paragraph below on reconciliation of forecasted earnings per
share).
Explanation of Unusual Charges and Credits
As previously disclosed, on June 30, 2003, the Company refinanced all of
its outstanding 9% senior subordinated notes with the proceeds of a $160
million expansion of the term loan component of its senior credit facility.
The Company expensed a total of $7.9 million of pre-tax costs in the second
quarter of 2003 associated with the refinancing consisting of the call premium
on the notes of $5.7 million and $2.2 million (non-cash) for the unamortized
deferred financing fees associated with original issue of the notes. The
current interest rate on the term loan expansion is equivalent to LIBOR plus
2.75%, for an approximate total of 4.0%.
During the second quarter of 2003, CONMED recorded pre-tax acquisition
related charges associated with the acquisitions of Bionx and Core Dynamics
amounting to $1.5 million for various transitional activities.
In the second quarter of 2003, the Company's pension plan settled pension
obligations with certain terminated employees, primarily with regard to the
sales-force reorganization on April 1, 2003, by lump-sum payment of accrued
benefits. Because Department of Labor rules with respect to lump-sum payment
calculations are different than the pension plan's assumptions regarding
discount rates, a non-cash, pre-tax loss was incurred amounting to $2.1
million. The Company recorded this expense in the second quarter of 2003.
In the first quarter of 2003, the Company recorded a special credit to
income that, together with first quarter acquisition charges, affected the
Company's results for the six months ended June 30, 2003. As previously
announced, in March 2003, the Company received $9.5 million as a settlement of
a dispute related to the 1997 acquisition of its orthopedic subsidiary,
Linvatec Corporation. Accordingly, the Company recorded the settlement, less
estimated legal expenses of $0.5 million, as a pre-tax gain of $9.0 million in
the first quarter of 2003. Offsetting this gain in the first quarter of 2003,
were pre-tax charges totaling $1.7 million associated with the integration of
the Company's previously announced Bionx, Core and ValMed acquisitions. In
addition, the Company incurred a $0.2 million pre-tax expense related to the
purchase on the open market of $2.6 million of the Company's 9% subordinated
bonds.
Reconciliation of Forecasted Earnings Per Share
The diluted earnings per share forecasted range of $0.35 to $0.38 for the
third quarter 2003 excludes any potential additional pension settlement
charges and acquisition related charges for the Bionx acquisition which, if
they occur, are not presently quantifiable. The Company expects to record in
an in-process research and development write-off associated with the Bionx
acquisition once an independent valuation has been completed, most likely in
the third quarter of 2003.
The diluted earnings per share forecasted range of $1.47 to $1.51 for the
year 2003 excludes the earnings per share net benefit of the lawsuit
settlement gain, acquisition, financing and pension settlement related charges
recorded in the first and second quarters of 2003 (explained above), and any
potential pension settlement and acquisition related charges which may occur
in the third and fourth quarters of 2003 which, if they occur, are not
presently quantifiable.
CONMED Profile
CONMED is a medical technology company specializing in instruments,
implants, and video equipment for arthroscopic sports medicine, and powered
surgical instruments, such as drills and saws, for orthopedic, ENT, neuro-
surgery, and other surgical specialties. The Company is also a leading
developer, manufacturer and supplier of RF electrosurgery systems used
routinely to cut and cauterize tissue in nearly all types of surgical
procedures worldwide, endoscopy products such as trocars, clip appliers,
scissors, and surgical staplers. The Company offers integrated operating room
design and intensive care unit service managers. The Company also
manufactures and sells a full line of ECG electrodes for heart monitoring and
other patient care products. Headquartered in Utica, New York, the Company's
2,600 employees distribute its products worldwide from eleven manufacturing
locations.
Forward Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2002; (iii)
cyclical purchasing patterns from customers, end-users and dealers; (iv)
timely release of new products, and acceptance of such new products by the
market; (v) the introduction of new products by competitors and other
competitive responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(in thousands except per share amounts)
(unaudited)
Three months ended Six months ended
June 30, June 30,
2002 2003 2002 2003
Net sales $111,269 $124,540 $224,474 $242,574
Cost of sales 51,711 59,082 105,815 115,048
Cost of sales,
nonrecurring - Note A -- 327 -- 739
Gross profit 59,558 65,131 118,659 126,787
Selling and
administrative 35,141 39,353 69,609 76,498
Research and development 4,078 4,378 7,902 8,081
Other expense - Note B, C -- 11,222 -- 3,730
39,219 54,953 77,511 88,309
Income from operations 20,339 10,178 41,148 38,478
Interest expense 6,355 5,861 12,983 11,399
Income before income taxes 13,984 4,317 28,165 27,079
Provision for income taxes 5,034 1,554 10,139 9,748
Net income $ 8,950 $ 2,763 $ 18,026 $ 17,331
Per share data:
Net Income
Basic $ .34 $ .10 $ .70 $ .60
Diluted .33 .09 .68 .59
Weighted average
common shares
Basic 26,584 28,910 25,735 28,892
Diluted 27,359 29,212 26,422 29,195
Note A - Included in cost of sales in the three and six months ended June
30, 2003 are $.3 million and $.7 million, respectively, in acquisition-related
costs
Note B - Included in other expense in the three months ended June 30, 2003
are the following: $7.9 million in losses on the early extinguishment of debt;
$2.1 million in pension settlement costs; and $1.2 million in other
acquisition-related costs.
Note C - Included in other expense in the six months ended June 30, 2003
are the following: a $9.0 million gain on the settlement of a contractual
dispute; $8.1 million in losses on the early extinguishment of debt;
$2.1 million in pension settlement costs; and $2.5 million in other
acquisition-related costs.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
ASSETS
(unaudited)
December 31, June 30,
2002 2003
Current assets:
Cash and cash equivalents $ 5,626 $ 2,360
Accounts receivable, net 58,093 63,242
Inventories 120,443 128,099
Other current assets 9,504 9,851
Total current assets 193,666 203,552
Property, plant and equipment, net. 95,608 96,109
Goodwill and other assets, net 452,866 497,299
Total assets $742,140 $796,960
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $ 2,631 $ 4,061
Accrued interest 3,794 510
Other current liabilities 51,549 50,699
Total current liabilities 57,974 55,270
Long-term debt 254,756 285,451
Other long-term liabilities 42,471 46,466
Total liabilities 355,201 387,187
Shareholders' equity:
Capital accounts 231,701 234,361
Retained earnings 162,391 179,722
Accumulated other comprehensive loss (7,153) (4,310)
Total equity 386,939 409,773
Total liabilities and shareholders' equity $742,140 $796,960
OTHER FINANCIAL INFORMATION
(unaudited, in thousands)
Three months ended Six months ended
June 30, June 30,
2002 2003 2002 2003
Depreciation $ 2,198 $ 2,534 $ 4,404 $ 4,908
Amortization 3,029 3,375 5,809 6,321
Capital expenditures 5,220 2,241 8,428 3,951
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE NONRECURRING ITEMS
(In thousands except per share amounts)
(unaudited)
Three months ended
June 30,
2002 2003
Reported net income (loss) $ 8,950 $ 2,763
Acquisition-related costs included
in cost of sales -- 327
Pension settlement costs -- 2,081
Other acquisition-related costs -- 1,229
Loss on early extinguishment of debt -- 7,912
Other expense -- 11,222
Nonrecurring expense before income taxes -- 11,549
Provision (benefit) for income taxes on
nonrecurring expense -- (4,157)
Net income before nonrecurring items. $ 8,950 $ 10,155
Per share data:
Reported net income
Basic $ 0.34 $ 0.10
Diluted 0.33 0.09
Net income before nonrecurring items
Basic $ 0.34 $ 0.35
Diluted 0.33 0.35
Management has provided the above reconciliation of net income before
nonrecurring items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE NONRECURRING ITEMS
(In thousands except per share amounts)
(unaudited)
Six months ended
June 30,
2002 2003
Reported net income $ 18,026 $ 17,331
Acquisition-related costs included
in cost of sales -- 739
Gain on settlement of a contractual dispute,
net of legal costs -- (9,000)
Pension settlement costs -- 2,081
Other acquisition-related costs -- 2,571
Loss on early extinguishment of debt -- 8,078
Other expense -- 3,730
Nonrecurring expense before income taxes -- 4,469
Provision (benefit) for income taxes on
nonrecurring expense -- (1,608)
Net income before nonrecurring items. $ 18,026 $ 20,192
Per share data:
Reported net income
Basic $ 0.70 $ 0.60
Diluted 0.68 0.59
Net income before nonrecurring items
Basic $ 0.70 $ 0.70
Diluted 0.68 0.69
Management has provided the above reconciliation of net income before
nonrecurring items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; Investors - Lauren Levine,
or Lanie Fladell, Media - Sean Leous, all of Morgen-Walke
Associates, +1-212-850-5600, for CONMED Corporation
|
